News GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
0.3155 ^USD	-82.76%		-79.65%	-86.63%

May. 06	Sector Update: Health Care Stocks Higher in Late Afternoon Trading	MT
May. 06	Sector Update: Health Care	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Higher in Late Afternoon Trading	May. 06	MT
Sector Update: Health Care	May. 06	MT
GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint	May. 06	MT
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	May. 06	BU
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia	May. 06	CI
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 25	BU
Transcript : GlycoMimetics, Inc., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
GlycoMimetics: Q4 Earnings Snapshot	Mar. 27	AQ
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023	Mar. 27	BU
GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
GlycoMimetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024	Mar. 13	BU
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference	Feb. 26	BU
GlycoMimetics Reports Inducement Grant under NASDAQ Listing Rule 5635(4)	Feb. 13	AQ
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Feb. 12	BU
GlycoMimetics, Inc. Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1A Healthy Volunteer Study of GMI-1687	Jan. 04	CI
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687	Jan. 04	BU
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	Jan. 03	AQ
GlycoMimetics, Thermo Fisher Unit Set Accord for Manufacturing Uproleselan for Acute Myeloid Leukemia	Jan. 02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Summary

Filters